Investigational drug · Phase 3
GM-CSF
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Neuroblastoma, Acute Myeloid Leukemia.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
894
Any phase or sponsor naming "GM-CSF"
First trial start
2018
Apr 3, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GM-CSF", any sponsor or status.
Conditions studied
As listed on its trial records.
- Neuroblastoma
- Acute Myeloid Leukemia
Approved drugs for the same conditions: Acute myeloid leukemia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "GM-CSF" as an intervention, largest first.
- Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive SubjectsPivotal-lookingRecruiting
Greenwich LifeSciences, Inc.Industry
NCT05232916 · 2,250 participants (planned) · Start Dec 16, 2022 · Primary completion Dec 2031
Drug: Placebo; GLSI-100 · For: Breast Cancer
Sites: Mobile, Alabama; Goodyear, Arizona; Tucson, Arizona · 179 sites in all
- A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast CancerPivotal-lookingTerminated
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03498716 · 2,199 participants · Start Aug 2, 2018 · Primary completion Aug 14, 2023
Drug: Atezolizumab; Paclitaxel and 2 more · For: Triple Negative Breast Cancer
Sites: Concord, California; Los Angeles, California; St. Helena, California · 364 sites in all
DendreonIndustry
NCT01306890 · 1,976 participants · Start Jan 27, 2011 · Primary completion Jan 17, 2017
Drug: sipuleucel-T · For: Advanced Prostate Cancer; Prostatic Neoplasms
Sites: Bessemer, Alabama; Birmingham, Alabama; Huntsville, Alabama · 333 sites in all
- Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First RemissionPivotal-lookingCompleted
Eastern Cooperative Oncology GroupResearch network
NCT00002514 · 1,929 participants · Start May 7, 1993 · Primary completion Dec 2006
Drug: sargramostim; asparaginase and 12 more · For: Leukemia
Sites: Aurora, Colorado; Boulder, Colorado; Colorado Springs, Colorado · 94 sites in all
- Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With NeuroblastomaPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00026312 · 1,449 participants · Start Oct 26, 2001 · Primary completion Jan 12, 2012
Drug: Aldesleukin; Dinutuximab and 2 more · For: Localized Resectable Neuroblastoma; Localized Unresectable Neuroblastoma; Recurrent Neuroblastoma and 3 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Phoenix, Arizona · 197 sites in all
- A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate CancerPivotal-lookingCompleted
Bavarian NordicIndustry
NCT01322490 · 1,297 participants · Start Nov 28, 2011 · Primary completion Sep 25, 2017
Drug: PROSTVAC-V; PROSTVAC-F and 2 more · For: Prostate Cancer Metastatic
Sites: Anchorage, Alaska; Scottsdale, Arizona; Berkeley, California · 220 sites in all
- Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerPivotal-lookingCompleted
Royal Liverpool University HospitalGovernment (non-federal)
NCT00425360 · 1,110 participants (planned) · Start Sep 2006
Drug: sargramostim; telomerase peptide vaccine GV1001 and 2 more · For: Pancreatic Cancer
Sites: Barnstaple, United Kingdom; Basingstoke, United Kingdom; Boston, United Kingdom · 45 sites in all
- Surgery in Treating Children With NeuroblastomaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT00003119 · 968 participants · Start Mar 1998 · Primary completion Mar 2006
Drug: filgrastim; sargramostim and 4 more · For: Neuroblastoma
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 235 sites in all
- Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By SurgeryPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT01989572 · 815 participants · Start Feb 23, 2000 · Primary completion Oct 8, 2012
Drug: Sargramostim; Tyrosinase Peptide · For: Iris Melanoma; Medium/Large Size Posterior Uveal Melanoma; Mucosal Melanoma and 17 more
Sites: Birmingham, Alabama; Mobile, Alabama; Scottsdale, Arizona · 148 sites in all
- Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammationPivotal-lookingCompleted
Kiniksa Pharmaceuticals International, plcIndustry
NCT04447469 · 814 participants · Start Jul 28, 2020 · Primary completion Nov 12, 2021
Drug: mavrilimumab · For: COVID
Sites: Los Angeles, California; San Diego, California; Chicago, Illinois · 32 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Anti-tumor efficacy of oncolytic herpes simplex viruses constructed by synthetic genomics in a murine colorectal carcinoma model and in human tumor cell lines.
Xiao H, Yin Q, Hu H, et al. · Virology 2027
- Zinc finger protein 24 enhances the pro-inflammatory activities of Tc17 cells and Tc17.1 cells in mouse collagen-induced arthritis.
Zhang S, Du X, Yang P, et al. · Autoimmunity 2026
- Prednisolone modulates CD8⁺ and regulatory T-cell activity to dampen response to immune checkpoint inhibitor therapy in melanoma.
Brown JR, Pedersen B, Long GV, et al. · Oncoimmunology 2026
- Pilose antler proteins attenuate cyclophosphamide-induced myelosuppression in mice and bone marrow mesenchymal stem cells.
Gao F, Xiang X, Xie Y, et al. · J Ethnopharmacol 2026
- Calmodulin kinase-like vesicle-associated protein (CAMKV) autoimmune encephalitis: Neurological & oncological accompaniments, treatments & outcomes.
Anissian D, Gilligan M, Lesnick CE, et al. · Transl Oncol 2026
- Proteomics and network biology insights into inflammation suppression during prolonged high-altitude hypoxia acclimatization.
Sharma P, Kumar Sharma N, Ahmad Y · Biochem Biophys Rep 2026
Also in development for Neuroblastoma
- APG-2575lisaftoclaxPhase 310 trials
Ascentage Pharma Group Inc. · CLL/SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- MK-2140Zilovertamab Vedotin, VLS-101Phase 39 trials
Merck & Co. · Diffuse Large B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, B-cell Acute Lymphoblastic Leukemia
- IRP101meta-fluorobenzylguanidine, 18F-MFBGPhase 34 trials
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) · Cardiovascular Diseases, Heart Failure, Ischemic Cardiomyopathy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.